If the Phase I trial is successful, Moderna plans to quickly initiate Phase II and Phase III trials of its Ebola vaccine.

Aug 4 (Reuters) - Moderna on Tuesday said it has begun its first human trial of an experimental vaccine to protect against ...

Phase 1 trial will evaluate safety and immune response for a strain of Ebola virus disease with no licensed vaccines ...

The trial, backed by up to $50 million from CEPI, comes as the Congo outbreak surpasses 3,700 confirmed cases and 1,600 deaths ...

The program is backed by the Coalition for Epidemic Preparedness Innovations, which has committed up to $50 million.

Moderna began a Phase 1 clinical trial of its experimental vaccine mRNA-1469 targeting the Bundibugyo strain of Ebola virus.

Moderna has begun a Phase 1 clinical trial of an Ebola vaccine set to target the Bundibugyo strain, which is currently ...

Moderna has started first-in-human testing of its mRNA vaccine against Bundibugyo Ebola virus (BDBV), now causing the ...

The vaccine relies on the same mRNA technology used in Moderna’s Covid-19 vaccine. Read more at straitstimes.com. Read more ...

The Phase 1 trial of the mRNA vaccine candidate will assess safety, determine the dosage range and identify potential side ...

Moderna launched a human trial of an experimental vaccine to protect against Bundibugyo Ebola strain that has killed more ...